TY - JOUR
T1 - Associations Between Changes in Plasma Renin Activity and Aldosterone Concentrations and Changes in Kidney Function After Treatment for Primary Aldosteronism
AU - JPAS/JRAS Study Group
AU - Kobayashi, Yusuke
AU - Haze, Tatsuya
AU - Yano, Yuichiro
AU - Tamura, Kouichi
AU - Kurihara, Isao
AU - Ichijo, Takamasa
AU - Yoneda, Takashi
AU - Katabami, Takuyuki
AU - Tsuiki, Mika
AU - Wada, Norio
AU - Ogawa, Yoshihiro
AU - Kawashima, Junji
AU - Sone, Masakatsu
AU - Inagaki, Nobuya
AU - Yamada, Tetsuya
AU - Okamoto, Ryuji
AU - Fujita, Megumi
AU - Kamemura, Kohei
AU - Yamamoto, Koichi
AU - Izawa, Shoichiro
AU - Tanabe, Akiyo
AU - Naruse, Mitsuhide
N1 - Funding Information:
This study was supported by research grants from the Japan Agency for Medical Research and Development (AMED) (grant numbers AMED JP17ek0109122 and JP20ek0109352). This study was also supported by a grant from the National Center for Health and Medicine, Japan (27-1402, 30-1008). We thank the JPAS/JRAS Study members for collecting the clinical data.
Funding Information:
This study was supported by research grants from the Japan Agency for Medical Research and Development (AMED) (grant numbers AMED JP17ek0109122 and JP20ek0109352 ). This study was also supported by a grant from the National Center for Health and Medicine , Japan ( 27-1402, 30-1008 ). We thank the JPAS/JRAS Study members for collecting the clinical data.
Publisher Copyright:
© 2020 International Society of Nephrology
PY - 2020/8
Y1 - 2020/8
N2 - Introduction: Greater reduction in estimated glomerular filtration rate (eGFR) after specific treatment for primary aldosteronism (PA) reflects improvement in glomerular hyperfiltration associated with PA and leads to better patient outcomes. However, little is known regarding the mechanisms underlying eGFR reduction after treatment for PA. Methods: We analyzed data from the nationwide PA registry in Japan. Patients were assigned to adrenalectomy (n = 438) and mineralocorticoid receptor (MR) antagonist (n = 746) groups. We assessed associations between changes in blood pressure (BP), plasma renin activity (PRA) and plasma aldosterone concentrations (PAC), and eGFR before and 6 months after treatment for both groups. Results: In a multivariable linear regression, the adjusted β values (95% confidence interval [CI]) for change in eGFR after treatment were −2.76 (−4.29, −1.22) ml/min per 1.73 m2 for PRA (per 3.2 ng/ml per hour), and 1.97 (1.08, 2.85) ml/min per 1.73 m2 for PAC (per 236.1 pg/ml) in the adrenalectomy group; and −0.45 (−0.89, −0.01) ml/min per 1.73 m2 for PRA and −0.72 (−1.62, 0.18) ml/min per 1.73 m2 for PAC in the MR antagonist group. Change in mean arterial pressure after treatment was not significantly associated with change in eGFR in either group. Changes in PRA and PAC but not BP before and 6 months after treatment for PA were associated with greater reductions in eGFR. Conclusion: Post-treatment improvements in glomerular hyperfiltration may be attributable to decreased MR activity in the kidneys, but not to reductions in systemic BP.
AB - Introduction: Greater reduction in estimated glomerular filtration rate (eGFR) after specific treatment for primary aldosteronism (PA) reflects improvement in glomerular hyperfiltration associated with PA and leads to better patient outcomes. However, little is known regarding the mechanisms underlying eGFR reduction after treatment for PA. Methods: We analyzed data from the nationwide PA registry in Japan. Patients were assigned to adrenalectomy (n = 438) and mineralocorticoid receptor (MR) antagonist (n = 746) groups. We assessed associations between changes in blood pressure (BP), plasma renin activity (PRA) and plasma aldosterone concentrations (PAC), and eGFR before and 6 months after treatment for both groups. Results: In a multivariable linear regression, the adjusted β values (95% confidence interval [CI]) for change in eGFR after treatment were −2.76 (−4.29, −1.22) ml/min per 1.73 m2 for PRA (per 3.2 ng/ml per hour), and 1.97 (1.08, 2.85) ml/min per 1.73 m2 for PAC (per 236.1 pg/ml) in the adrenalectomy group; and −0.45 (−0.89, −0.01) ml/min per 1.73 m2 for PRA and −0.72 (−1.62, 0.18) ml/min per 1.73 m2 for PAC in the MR antagonist group. Change in mean arterial pressure after treatment was not significantly associated with change in eGFR in either group. Changes in PRA and PAC but not BP before and 6 months after treatment for PA were associated with greater reductions in eGFR. Conclusion: Post-treatment improvements in glomerular hyperfiltration may be attributable to decreased MR activity in the kidneys, but not to reductions in systemic BP.
UR - http://www.scopus.com/inward/record.url?scp=85087942581&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087942581&partnerID=8YFLogxK
U2 - 10.1016/j.ekir.2020.06.012
DO - 10.1016/j.ekir.2020.06.012
M3 - Article
AN - SCOPUS:85087942581
SN - 2468-0249
VL - 5
SP - 1291
EP - 1297
JO - Kidney International Reports
JF - Kidney International Reports
IS - 8
ER -